<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04952805</url>
  </required_header>
  <id_info>
    <org_study_id>A0001B</org_study_id>
    <nct_id>NCT04952805</nct_id>
  </id_info>
  <brief_title>Study to Select the Dose and Evaluate Safety and Efficacy of Monoclonal Antibody in Adult With Recently Diagnosed Asymptomatic to Moderately Severe COVID-19.</brief_title>
  <official_title>Randomized, Placebo-controlled, Double-blind, Multicenter, Seamless Adaptive Phase II-III Clinical Trial to Select the Dose and Evaluate Safety and Efficacy of MAD0004J08 Monoclonal Antibody in Adult Patients With Recently Diagnosed Asymptomatic to Moderately Severe COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Toscana Life Sciences Sviluppo s.r.l.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Toscana Life Sciences Sviluppo s.r.l.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      MAD0004J08, the experimental drug, is a potent neutralizing IgG1 monoclonal antibody (mAb)&#xD;
      targeting the spike protein of SARS-CoV-2. MAD0004J08 blocks viral attachment and entry into&#xD;
      human cells and neutralizes the virus. Because of its high affinity and potency, MAD0004J08&#xD;
      may accelerate clearance of the virus and prevent clinical deterioration of COVID-19&#xD;
      patients, especially when administered shortly after infection, and prevent SARS-CoV-2&#xD;
      infection in uninfected subjects. Because of its high potency, MAD0004J08 is expected to be&#xD;
      effective at low doses (mg range) and thus will be administered by intramuscular (IM)&#xD;
      injection, as opposed to the intravenous bolus required by high dose mAbs.&#xD;
&#xD;
      The goals of this Phase II-III seamless adaptive clinical trial are:&#xD;
&#xD;
      Stage-1 (Phase II)&#xD;
&#xD;
        1. Select one dose level for progression to Stage-2 Stage-1 + Stage-2 (Phase III)&#xD;
&#xD;
        2. Provide confirmatory evidence of safety and efficacy for regulatory approval.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is designed as a randomized, stratified, placebo-controlled doubleblind,&#xD;
      multicenter, seamless adaptive study. The target study population is adult patients ≥ 18&#xD;
      years of age with recently diagnosed (≤ 3 days from 1st positive swab taken) asymptomatic to&#xD;
      moderately severe COVID-19 at baseline. Patients with comorbidities will be allowed in the&#xD;
      study assuming all inclusion and exclusion criteria are met. Participants will not require&#xD;
      hospitalization at baseline.&#xD;
&#xD;
      The trial is designed in two stages:&#xD;
&#xD;
        -  Stage I: participants will be randomized (1:1:1 ratio) to one of the one of the&#xD;
           following three study cohorts:&#xD;
&#xD;
        -  MAD0004J08 400 mg, single dose&#xD;
&#xD;
        -  MAD0004J08 100 mg, single dose&#xD;
&#xD;
        -  Placebo, single dose The collected data will be analysed following a pre-planned interim&#xD;
           analysis plan. Based on the results of this analysis the Data Monitoring Committee (DMC)&#xD;
           will recommend whether the study should advance to Stage-2, and if so, will recommend&#xD;
           selection of one of the two MAD0004J08 treatments for Stage-2. Alternatively, the DMC&#xD;
           will recommend stopping the study. Final decisions will be made by an unblinded&#xD;
           sub-group of the Steering Committee (SC), including senior Sponsor representatives,&#xD;
           based on summary results.&#xD;
&#xD;
        -  Stage-2: participants will be randomized (1:1 ratio) to one of two treatments:&#xD;
&#xD;
        -  MAD0004J08, dose level selected in Stage-1, single dose&#xD;
&#xD;
        -  Placebo, single dose Twelve (12) study visits and 2 telephone calls are scheduled for&#xD;
           each participant over approximately 168 days. Additional ad-hoc visit(s) may be&#xD;
           necessary to confirm eradication of SARS-CoV-2 from the upper respiratory tract (URT)&#xD;
           following the 1st negative swab.&#xD;
&#xD;
      At Visit 1 (baseline) all participants will undergo testing for serum IgA and IgG vs. the&#xD;
      spike (S) protein, and IgG vs. nucleocapsid (N) protein: participants testing negative to all&#xD;
      three antibodies at baseline are referred to as seronegative; participants testing positive&#xD;
      to any of the three antibodies at baseline are referred to as seropositive. Due to the need&#xD;
      to minimize time between diagnosis and intervention, screening procedures, baseline&#xD;
      procedures, randomization and administration of study treatment will occur on day 1.&#xD;
&#xD;
      Visits from Day 3 to Day 21 (Visits 2 to 9) will be conducted by study staff at the&#xD;
      participant's home, unless the participant is hospitalized. Visits from Day 28 to Day 168&#xD;
      (Visits 10 to 12) will be conducted at the study center. Participants requiring&#xD;
      hospitalization during the study period are to be hospitalized at the study center where&#xD;
      Visit 1 was conducted.&#xD;
&#xD;
      At each scheduled visit nasopharyngeal swabs will be carried out. Additional swabs may be&#xD;
      taken ad hoc to confirm eradication after the 1st negative swab.&#xD;
&#xD;
      Safety and efficacy endpoints will be analyzed as appropriate in two target populations (all&#xD;
      randomized participants (ALL) and seronegative randomized participants (SEROneg) and three&#xD;
      time-windows ( baseline (Visit 1) to end of Stage-1 or dropout (interim analysis), baseline&#xD;
      (Visit 1) to end of Stage-2 or dropout (primary analysis) and baseline (Visit 1) to end of&#xD;
      study (Visit 12) or dropout (final analysis).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severe (Grade 3) unsolicited AEs and/or serious unsolicited AEs (SAEs).</measure>
    <time_frame>From admission to discharge - Assessed as day 0</time_frame>
    <description>Proportion of participants with severe (Grade 3) unsolicited AEs and/or serious unsolicited AEs (SAEs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to SARS-CoV-2 clearance in the URT.</measure>
    <time_frame>From baseline (visit 1) up to day 168 ± 7 (visit 12)</time_frame>
    <description>Evaluation of the time required for the elimination of SARS-CoV-2 in the URT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unsolicited AEs, including clinically relevant laboratory and ECG abnormalities.</measure>
    <time_frame>From baseline (visit 1) up to day 168 ± 7 (visit 12)</time_frame>
    <description>Proportion of participants with unsolicited AEs, including clinically relevant laboratory and ECG abnormalities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited local AEs at the injection site</measure>
    <time_frame>From baseline (visit 1) up to day 28 (Visit 10)</time_frame>
    <description>Proportion of participants with solicited local AEs at the injection site. Will be considered: pain, swelling and redness at the injection site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who develop ADA.</measure>
    <time_frame>At baseline (visit 1), at day 7 (visit 4), at day 28 (visit 10), at day 56 ± 7 (visit 11) and at day 168 ± 7 (visit 12)</time_frame>
    <description>Proportion of participants who develop ADA. The first 60 randomized participants will be tested for ADA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 clearance in the URT</measure>
    <time_frame>At baseline (visit 1), at day 7 (visit 4), at day 28 (visit 10), at day 56 ± 7 (visit 11) and at day 168 ± 7 (visit 12)</time_frame>
    <description>Proportion of participants with SARS-CoV-2 clearance in the Upper Respiratory Tract (URT) at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 viral load in nasopharyngeal swab</measure>
    <time_frame>From baseline (visit 1) up to day 168 ± 7 (visit 12)</time_frame>
    <description>SARS-CoV-2 viral load (number of copies) in nasopharyngeal swab, as measured by RT-PCR at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SPO2% and lowest SpO2 % post baseline.</measure>
    <time_frame>From baseline (visit 1) up to day 168 ± 7 (visit 12)</time_frame>
    <description>SPO2 % value at each visit and lower SpO2 % after baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SpO2 % &lt; 94%.</measure>
    <time_frame>From baseline (visit 1) up to day 168 ± 7 (visit 12)</time_frame>
    <description>Proportion of participants with SpO2 % &lt; 94%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with increased dose home oxygen therapy</measure>
    <time_frame>From baseline (visit 1) up to day 168 ± 7 (visit 12)</time_frame>
    <description>Proportion of participants with newly established or increased dose home oxygen therapy increased home oxygen therapy (only applies to patients with underlying conditions other than COVID-19 requiring such therapy, e.g., COPD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) of COVID-19 total symptom score (range: 0-24).</measure>
    <time_frame>From baseline (visit 1) up to day 168 ± 7 (visit 12)</time_frame>
    <description>Assessment of COVID-19 total symptom score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants requiring hospitalization</measure>
    <time_frame>From event start (day 0) through event completion</time_frame>
    <description>Proportion of participants requiring hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative time of hospital stay in days.</measure>
    <time_frame>From event start (day 0) through event completion</time_frame>
    <description>Number of days the participant was hospitalised</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalized participants requiring supplemental oxygen therapy.</measure>
    <time_frame>From event start (day 0) through event completion</time_frame>
    <description>Proportion of hospitalized participants requiring supplemental oxygen therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative time of hospitalized oxygen therapy in days.</measure>
    <time_frame>From event start (day 0) through event completion</time_frame>
    <description>Number of days the hospitalized participant required oxygen therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants admitted to intensive care unit (ICU).</measure>
    <time_frame>From event start (day 0) through event completion</time_frame>
    <description>Proportion of participants admitted to intensive care unit (ICU).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative time of ICU stay in days.</measure>
    <time_frame>From event start (day 0) through event completion</time_frame>
    <description>Number of days the hospitalized participant stay in therapy intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality.</measure>
    <time_frame>From baseline (visit 1) to through study completion</time_frame>
    <description>Analysis of all All-cause mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD0004J08 serum concentration.</measure>
    <time_frame>From baseline (visit 1) up to day 168 ± 7 (visit 12)</time_frame>
    <description>Evaluation of MAD0004J08 serum concetration</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Interventional Arm _400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To all the patients enrolled is admistrated with single dose of MAD0004J08 400 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interventional Arm _100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To all the patients enrolled is admistrated with single dose of MAD0004J08 100 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>To all the patients enrolled is admistrated with single dose of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAD0004J08</intervention_name>
    <description>MAD0004J08 is a human monoclonal Antibody (mAb), 2.5 mL 2R vial available in two dose: 100 mg and 400 mg. The pharmaceutical form is solution for intramuscular injection.</description>
    <arm_group_label>Interventional Arm _100 mg</arm_group_label>
    <arm_group_label>Interventional Arm _400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching to MAD0004J08, 2.5 mL 2R vial. The pharmaceutical form is solution for intramuscular injection.</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent taken before any study procedure from any patient&#xD;
             capable of giving consent, or, when the patient is incapable of doing so, by his or&#xD;
             her legal/authorized representative.&#xD;
&#xD;
          -  Age ≥18 years. At least 30% of participants will be ≥ 65 years old.&#xD;
&#xD;
          -  First nasopharyngeal swab testing positive for SARS-CoV-2 by RT-PCR taken no more than&#xD;
             3 days before randomization (Visit 1). Results of &quot;rapid&quot; semiquantitative tests are&#xD;
             not acceptable.&#xD;
&#xD;
          -  Asymptomatic to moderately symptomatic outpatients with no need for immediate&#xD;
             hospitalization: grade 1, or grade 2 or grade 3 of Clinical Severity Scale.&#xD;
&#xD;
          -  No childbearing potential (post-menopause, surgically-induced, or&#xD;
             pharmacologically-induced sterility) or, if of childbearing potential, negative&#xD;
             urinary pregnancy test (women) and commitment to use at least 2 forms of contraception&#xD;
             for at least 168 days from administration of study drug (men and women).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe or critical COVID-19: grade 4 or grade 5 of clinical severity scale.&#xD;
&#xD;
          -  Current hospitalization and/or hospitalization or emergency room visit in the past 14&#xD;
             days.&#xD;
&#xD;
          -  Need for immediate hospitalization for any reason in the investigator's opinion.&#xD;
&#xD;
          -  Severe liver disease as determined by values of ALT and/or AST &gt;5x upper limit of&#xD;
             normal (ULN) and/or history of liver cirrhosis.&#xD;
&#xD;
          -  Severe renal disease as determined by estimated creatinine clearance (CcCl) &lt;30 mL/min&#xD;
             or serum creatinine &gt;2 mg/dL (&gt;176.8 μmol/L) or ongoing renal dialysis.&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt; 1000/μL.&#xD;
&#xD;
          -  Demyelinating and connective tissue disease.&#xD;
&#xD;
          -  Active tuberculosis or suspected active bacterial, fungal, viral, or other infection&#xD;
             (besides COVID- 19).&#xD;
&#xD;
          -  Any condition that in the Investigator's opinion may be negatively affected by the&#xD;
             study treatments and/or study procedures.&#xD;
&#xD;
          -  Any condition, including psychiatric disorders, alcohol, or substance abuse, which in&#xD;
             the Investigator's opinion may interfere with completion of the study procedures.&#xD;
&#xD;
          -  Any condition with life expectancy &lt;6 months in the Investigator's opinion.&#xD;
&#xD;
          -  Ongoing or planned pregnancy.&#xD;
&#xD;
          -  Ongoing breast feeding.&#xD;
&#xD;
          -  History of life-threatening event in the 1 month before Visit 1.&#xD;
&#xD;
          -  History of surgery in the 1 month before Visit 1.&#xD;
&#xD;
          -  History of treatment with blood components in the 6 months before Visit 1.&#xD;
&#xD;
          -  History of cancer treated with chemotherapy in the 6 months before Visit 1.&#xD;
&#xD;
          -  History of solid organ transplant at any time before Visit 1.&#xD;
&#xD;
          -  History of severe and/or serious allergic reaction to monoclonal antibodies or any&#xD;
             component of MAD0004J08, including anaphylaxis at any time before Visit 1.&#xD;
&#xD;
          -  Treatment with an investigational drug or vaccine within 5 half-lives or 30 days&#xD;
             (whichever is longer) of randomization.&#xD;
&#xD;
          -  Treatment at any time with monoclonal antibodies bamlanivimab, bamlanivimab +&#xD;
             etesevimab combination, and casiribimab + imdevimab combination.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simone Lanini</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS INMI Lazzaro Spallanzani - Istituto nazionale Malattie Infettive</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierpaola Borgonovo</last_name>
    <phone>003903626331</phone>
    <email>info.studiclinici@opis.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS INMI Lazzaro Spallanzani - Istituto nazionale Malattie Infettive</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simone Lanini</last_name>
      <phone>+390655170923</phone>
      <email>simone.lanini@inmi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliera San Giuseppe Moscati</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Amitrano</last_name>
      <phone>+390818295624</phone>
      <email>amitranomaria@virgilio.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi di Firenze</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Bartoloni</last_name>
      <phone>0557949431</phone>
      <email>alessandro.bartoloni@unifi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedali Riuniti di Foggia - Università degli Studi di Fog</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Lo Caputo</last_name>
      <email>sergio.locaputo@unifg.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Gori</last_name>
      <email>andrea.gori@policlinico.mi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliera dei Colli - P.O. &quot;D. Cotugno&quot;</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Maria Fusco</last_name>
      <email>francescomaria.fusco@ospedalideicolli.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlo Ferrari</last_name>
      <phone>+390521702762</phone>
      <email>carlo.ferrari@unipr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo di Pavia</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raffaele Bruno</last_name>
      <email>raffaele.bruno@unipv.it</email>
    </contact>
    <contact_backup>
      <phone>+390382503689</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Azienda USL Ospedale &quot;Guglielmo da Saliceto&quot;</name>
      <address>
        <city>Piacenza</city>
        <zip>29121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mauro Codeluppi</last_name>
      <phone>+390523303700</phone>
      <email>M.Codeluppi@ausl.pc.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Pisana - Ospedale di Cisanello</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Menichetti</last_name>
      <email>f.menichetti@ao-pisa.toscana.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Santa Maria alle Scotte - Università di Siena</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Frediani</last_name>
    </contact>
    <contact_backup>
      <email>bruno.frediani@unisi.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ospedale di Cattinara</name>
      <address>
        <city>Trieste</city>
        <zip>34149</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Confalonieri</last_name>
      <email>mconfalonieri@units.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASL di Vercelli - Ospedale Sant'Andrea</name>
      <address>
        <city>Vercelli</city>
        <zip>13100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvio Borrè</last_name>
      <email>silvio.borre@aslvc.piemonte.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Integrata di Verona</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Evelina Tacconelli</last_name>
      <phone>+390458128243</phone>
      <email>evelina.tacconelli@univr.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

